In summary, clinical data suggest that the IL-1 cytokine family contributes to cardiac dysfunction and that blocking IL-1 with anakinra or canakinumab improves cardiac function and prevents hospitalization in patients with HF. The gene discussed is IL1B; the disease is hydrops fetalis.